A detailed history of Wealth Effects LLC transactions in Scynexis Inc stock. As of the latest transaction made, Wealth Effects LLC holds 102,000 shares of SCYX stock, worth $103,020. This represents 0.06% of its overall portfolio holdings.

Number of Shares
102,000
Previous 111,500 8.52%
Holding current value
$103,020
Previous $223,000 32.29%
% of portfolio
0.06%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$1.27 - $2.23 $12,065 - $21,185
-9,500 Reduced 8.52%
102,000 $151,000
Q2 2024

Aug 02, 2024

SELL
$1.4 - $2.77 $4,200 - $8,310
-3,000 Reduced 2.62%
111,500 $223,000
Q1 2024

Apr 22, 2024

SELL
$1.39 - $2.21 $4,170 - $6,630
-3,000 Reduced 2.55%
114,500 $168,000
Q4 2023

Jan 29, 2024

BUY
$1.56 - $2.24 $38,220 - $54,880
24,500 Added 26.34%
117,500 $262,000
Q3 2023

Oct 16, 2023

BUY
$1.93 - $3.64 $42,363 - $79,898
21,950 Added 30.89%
93,000 $212,000
Q2 2023

Jul 18, 2023

BUY
$2.38 - $3.67 $23,800 - $36,700
10,000 Added 16.38%
71,050 $209,000
Q1 2023

May 04, 2023

SELL
$1.15 - $3.0 $575 - $1,500
-500 Reduced 0.81%
61,050 $183,000
Q4 2022

Feb 02, 2023

SELL
$1.46 - $2.94 $37,960 - $76,440
-26,000 Reduced 29.7%
61,550 $96,000
Q3 2022

Nov 14, 2022

SELL
$1.83 - $2.93 $3,660 - $5,860
-2,000 Reduced 2.23%
87,550 $210,000
Q2 2022

Aug 03, 2022

SELL
$1.77 - $3.87 $4,425 - $9,675
-2,500 Reduced 2.72%
89,550 $167,000
Q1 2022

May 16, 2022

BUY
$3.56 - $6.66 $15,130 - $28,305
4,250 Added 4.84%
92,050 $360,000
Q4 2021

Feb 09, 2022

BUY
$4.94 - $7.69 $433,732 - $675,182
87,800 New
87,800 $536,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Wealth Effects LLC Portfolio

Follow Wealth Effects LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Effects LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Effects LLC with notifications on news.